Currently in the United States, a prostate cancer drug is being touted in a novel way: The claimed primary benefit of the drug is not that it reduces the risk of the disease, but rather
I had the singular privilege of being the team leader for the “juried analysis” published in the inaugural issue of APS’s Psychological Science in the Public Interest (PSPI). Robyn Dawes, John Monahan and I co-authored
A total of 11 psychological scientists, all of whom are APS Fellows, have been elected as members of the 2016 class of the American Academy of Arts & Sciences. The academy is “one of the